Supplementary Table 1 Unconditional univariate logistic analysis of factors associated with FOLFOXIRI in first-line chemotherapy

Characteristics	Patients (*n*)	Patients treated with FOLFOXIRI (*n*)	OR (95%CI)	*P* value
Demographic parameters				
Age, years	288	165	1.014 (0.991-1.039)	0.236
Missing	1	0		
Gender				
Male	170	97	1.00 (Reference)	
Female	119	68	1.003 (0.625-1.611)	0.989
Familial history of cancer				
No	121	89	1.00 (Reference)	
Yes	114	75	0.691 (0.395-1.210)	0.196
Missing	54	1		
Personal history of cancer				
No	249	139	1.00 (Reference)	
Yes	36	24	1.583 (0.758-3.306)	0.222
Missing	4	2		
Pathological parameters				
Stage at diagnosis				
Localized	33	13	1.00 (Reference)	
Locally advanced	78	60	5.128 (2.139-12.298)	
Metastatic	178	92	1.646 (0.772-3.511)	< 0.001
Primary tumor site				
Head	146	93	1.00 (Reference)	
Body and/or tail	141	71	0.578 (0.361-0.927)	0.023
Missing	2	1		
Histological grade				

Well or Moderately differentiated	84	39	1.00 (Reference)		
Poorly differentiated or Undifferentiated	32	23	2.949	(1.221-7.122)	0.016
Missing	173	10			
Tumor extension					
Stage at chemotherapy initiation					
Locally advanced	74	60	1.00 (Reference)		
Metastatic	215	105	0.223	(0.117-0.423)	< 0.001
Number of metastatic sites					
0	74	60	1.00 (Reference)		
1	143	74	0.250	(0.128-1.488)	
≥ 2	72	31	0.176	(0.084-0.372)	< 0.001
Lymph node metastases					
No	248	153	1.00 (Reference)		
Yes	41	12	0.257	(0.125-0.528)	< 0.001
Liver metastases					
No	121	84	1.00 (Reference)		
Yes	168	81	0.410	(0.251-0.670)	< 0.001
Peritoneal metastases					
No	243	134	1.00 (Reference)		
Yes	46	31	1.681	(0.863-3.273)	0.127
Lung metastases					
No	248	146	1.00 (Reference)		
Yes	41	19	0.603	(0.311-1.172)	0.136
Other metastases					
No	278	162	1.00 (Reference)		
Yes	11	3	0.269	(0.070-1.034)	0.056
Clinical parameters					

Performance status (WHO)					
0	96	54	1.00 (Reference)		
1	169	103	1.214	(0.730-2.017)	
≥ 2	20	8	0.519	(0.194-1.383)	0.195
Missing	4	0			
Body mass index, kg/m^2	280	165	0.967	(0.920-1.016)	0.182
Missing	9	0			
Pain					
No	173	83	1.00 (Reference)		
Yes	112	80	2.711	(1.633-4.501)	< 0.001
Missing	4	2			
Jaundice					
No	262	148	1.00 (Reference)		
Yes	25	17	1.637	(0.682-3.927)	0.270
Missing	2	0			
Ascites					
No	274	157	1.00 (Reference)		
Yes	11	6	0.894	(0.266-2.999)	0.856
Missing	4	2			
Biological parameters					
Albumin, g/L	161	85	0.881	(0.832-0.933)	< 0.001
Missing	128	80			
Lymphocytes, mm^3					
< 1000	22	10	1.462	(0.592-3.613)	0.410
≥ 1000	146	53	1.00 (Reference)		
Missing	121	102			
Neutrophil-to-lymphocyte ratio					
< 5	124	42	1.00 (Reference)		

≥ 5	44	21	1.783	(0.886-3.585)	0.105
Missing	121	102			
CA19-9, UI/mL	252	131	1.000	(1.000-1.000)	0.452
Missing	37	34			
Previous treatment					
Primary tumor resection					
Yes	35	17	1.00 (Reference)		
No	254	148	1.478	(0.728-3.002)	0.279
Adjuvant chemotherapy					
Yes	27	15	1.00 (Reference)		
No	262	150	1.072	(0.483-2.379)	0.865

Logistic regression models used to estimate association of the parameters with FOLFOXIRI regimen. Values of $P < 0.05$ were considered statistically significant and all tests were two-sided. OR: Odds ratio; CI: Confidence interval; WHO: World Health Organization; CA19-9: Carbohydrate antigen 19-9.

Supplementary Table 2 Unconditional multivariate logistic analysis of factors associated with FOLFOXIRI in first-line chemotherapy for the construction of the propensity score (*n* = 283)

Characteristics	Patients (*n*)	Patients treated with FOLFOXIRI (*n*)	OR (95%CI)	*P* value
Primary tumor site				
Head	143	91	1.00 (Reference)	
Body and/or tail	140	71	0.669 (0.383-1.170)	0.159
Stage at diagnosis				
Localized	32	13	1.00 (Reference)	
Locally advanced	75	57	0.663 (0.113-3.869)	
Metastatic	176	92	2.120 (0.891-5.047)	0.143
Stage at chemotherapy initiation				
Locally advanced	71	57	1.00 (Reference)	
Metastatic	212	105	0.179 (0.025-1.262)	0.084
Number of metastatic sites				
0	71	57	1.00 (Reference)	
1	142	74	0.944 (0.460-1.937)	
≥ 2	70	31	NA	0.876
Lymph node metastases				
No	244	150	1.00 (Reference)	
Yes	39	12	0.325 (0.132-0.799)	0.014
Liver metastases				
No	117	81	1.00 (Reference)	
Yes	166	81	0.639 (0.304-1.345)	0.239
Pain				
No	172	83	1.00 (Reference)	

Yes	111	79	2.937	(1.695-5.089)	< 0.001

Logistic regression models used to estimate association of the parameters with FOLFOXIRI regimen. Values of P<0.05 were considered statistically significant and all tests were two-sided. OR: Odds ratio; CI: Confidence interval.

Supplementary Table 3 Patient characteristics of the entire metastatic population according to first-line chemotherapy, *n* (%)

Characteristics	FOLFIRINOX (*n* = 110)	FOLFOXIRI (*n* = 105)	*P* value
Demographic parameters			
Age, median [IQR], yr	60.0 [53.0-65.2]	62.0 [53.4-67.0]	0.147
Missing	1	0	
Gender			0.386
Male	66 (60.0)	69 (65.7)	
Female	44 (40.0)	36 (34.3)	
Familial history of cancer			0.131
No	26 (42.6)	57 (54.8)	
Yes	35 (57.4)	47 (45.2)	
Missing	49	1	
Personal history of cancer			0.056
No	98 (90.7)	85 (81.7)	
Yes	10 (9.3)	19 (18.3)	
Missing	2	1	
Pathological parameters			
Stage at diagnosis			0.406
Localized	18 (16.4)	13 (12.4)	
Advanced	92 (83.6)	92 (87.6)	
Primary tumor site			0.520
Head	42 (38.5)	45 (42.9)	
Body and/or tail	67 (61.5)	60 (57.1)	
Missing	1	0	
Histological grade			0.014
Well or Moderately differentiated	40 (81.6)	27 (58.7)	
Poorly differentiated or Undifferentiated	9 (18.4)	19 (41.3)	
Missing	61	59	
Tumor extension			
Number of metastatic sites			0.229
1	69 (62.7)	74 (70.5)	
≥ 2	41 (37.3)	31 (29.5)	
Lymph node metastases			0.005
No	81 (73.6)	93 (88.6)	

Yes	29 (26.4)	12 (11.4)	
Liver metastases			0.730
No	23 (20.9)	24 (22.9)	
Yes	87 (79.1)	81 (77.1)	
Peritoneal metastases			0.005
No	95 (86.4)	74 (70.5)	
Yes	15 (13.6)	31 (29.5)	
Lung metastases			0.722
No	88 (80.0)	86 (81.9)	
Yes	22 (20.0)	19 (18.1)	
Other metastases			0.142
No	102 (92.7)	102 (97.1)	
Yes	8 (7.3)	3 (2.9)	
Clinical parameters			
Performance status (WHO)			0.086
0	36 (34.0)	30 (28.6)	
1	59 (55.7)	71 (67.6)	
≥ 2	11 (10.4)	4 (3.8)	
Missing	4	0	
Body mass index, kg/m^2	23.9 [21.2-27.8]	23.1 [20.8-26.1]	0.167
Missing	9	0	
Pain			0.005
No	77 (71.3)	55 (52.4)	
Yes	31 (28.7)	50 (47.6)	
Missing	2	0	
Jaundice			0.272
No	102 (94.4)	95 (90.5)	
Yes	6 (5.6)	10 (9.5)	
Missing	2	0	
Ascites			0.721
No	103 (95.4)	99 (94.3)	
Yes	5 (4.6)	6 (5.7)	
Missing	2	0	
Biological parameters			
Albumin, median [IQR], g/L	39.0 [37.0-42.6]	34.6 [29.0-39.0]	<0.001
Missing	41	52	

Lymphocytes, median [IQR], mm^3			0.066
< 1000	10 (10.7)	9 (23.1)	
≥ 1000	83 (89.3)	30 (76.9)	
Missing	17	66	
Neutrophil-to-lymphocyte ratio, median [IQR]			0.010
< 5	71 (76.3)	21 (53.9)	
≥ 5	22 (23.7)	18 (46.1)	
Missing	17	66	
CA19-9, median [IQR], UI/mL	1077.0 [76.7-7400.0]	1333.0 [208.7-12956.0]	0.184
Missing	3	23	
Previous treatment			
Primary tumor resection			0.642
Yes	16 (14.5)	13 (12.4)	
No	94 (85.5	92 (87.6)	
Adjuvant chemotherapy			0.904
Yes	12 (10.9)	12 (11.4)	
No	98 (89.1)	93 (88.6)	

χ^2 tests or Fisher's exact tests used to compare proportions, and Wilcoxon tests used to compare continuous variables between FOLFIRINOX and FOLFOXIRI groups. All statistical tests were two-sided. CA19-9: Carbohydrate antigen 19-9; IQR: Interquartile range; WHO: World Health Organization.

Supplementary Table 4 Outcomes of the entire metastatic population according to first-line chemotherapy, *n* (%)

Outcomes	FOLFIRINOX (*n* = 110)	FOLFOXIRI (*n* = 105)	*P* value
Number of cycles, median [IQR]	11.0 [6.0-13.0]	7.0 [4.0-14.0]	0.110
Missing	1	0	
RECIST best response			0.096
Complete or partial response	47 (48.0)	31 (38.3)	
Stability	26 (26.5)	17 (21.0)	
Progression	25 (25.5)	33 (40.7)	
Missing	12	24	
Toxicity of grade 3 or 4			0.201
No	83 (79.1)	75 (71.4)	
Yes	22 (20.9)	30 (28.6)	
Digestive	5 (4.8)	10 (9.5)	
Hematology	1 (0.9)	5 (4.8)	
Neurology	9 (8.5)	10 (9.5)	
Other	7 (6.7)	5 (4.8)	
Missing	5	0	
Reason for discontinuation			0.731
Progression	78 (71.6)	80 (76.2)	
Toxicity	8 (7.3)	7 (6.7)	
Other	23 (21.1)	18 (17.1)	
Missing	1	0	
Maintenance			0.055
Yes	53 (48.2)	37 (35.2)	
No	57 (51.8)	68 (64.8)	
Second-line chemotherapy administration			0.504
Yes	82 (74.6)	74 (70.5)	
No	28 (25.4)	31 (29.5)	

χ^2 tests or Fisher's exact tests used to compare proportions, and Wilcoxon tests used to compare continuous variables between FOLFIRINOX and FOLFOXIRI groups. All statistical tests were two-sided. IQR: Interquartile range.

Supplementary Table 5 Unconditional univariate logistic analysis of factors associated with FOLFOXIRI in first-line chemotherapy in patients with metastatic disease

Characteristics	Patients (*n*)	Patients treated with FOLFOXIRI (*n*)	OR (95%CI)	*P* value
Demographical parameters				
Age, years	214	105	1.020 (0.992-1.049)	0.159
Missing	1	0		
Gender				
Male	135	69	1.00 (Reference)	
Female	80	36	0.783 (0.449-1.363)	0.387
Familial history of cancer				
No	83	57	1.00 (Reference)	
Yes	82	47	0.613 (0.324-1.159)	0.132
Missing	50	1		
Personal history of cancer				
No	183	85	1.00 (Reference)	
Yes	29	19	2.190 (0.966-4.968)	0.061
Missing	3	1		
Pathological parameters				
Stage at diagnosis				
Localized	31	13	1.00 (Reference)	
Advanced	184	92	1.385 (0.641-2.990)	0.407
Primary tumor site				
Head	87	45	1.00 (Reference)	
Body and/or tail	127	60	0.836 (0.484-1.443)	0.520
Missing	1	0		
Histological grade				
Well or Moderately differentiated	67	27	1.00 (Reference)	

Poorly differentiated or Undifferentiated	28	19	3.127	(1.232-7.936)	0.016
Missing	120	59			
Tumor extension					
Number of metastatic sites					
1	143	74	1.00 (Reference)		
≥ 2	72	31	0.705	(0.399-1.247)	0.230
Lymph node metastases					
No	174	93	1.00 (Reference)		
Yes	41	12	0.360	(0.173-0.752)	0.007
Liver metastases					
No	47	24	1.00 (Reference)		
Yes	168	81	0.892	(0.467-1.704)	0.730
Peritoneal metastases					
No	169	74	1.00 (Reference)		
Yes	46	31	2.653	(1.334-5.274)	0.005
Lung metastases					
No	174	86	1.00 (Reference)		
Yes	41	19	0.884	(0.447-1.748)	0.723
Other metastases					
No	204	102	1.00 (Reference)		
Yes	11	3	0.375	(0.097-1.454)	0.156
Clinical parameters					
Performance status (WHO)					
0	66	30	1.00 (Reference)		
1	130	71	1.444	(0.797-2.618)	
≥ 2	15	4	0.436	(0.126-1.512)	0.098
Missing	4	0			

Body mass index, kg/m^2	206	105	0.967	(0.915-1.022)	0.239
Missing	9	0			
Pain					
No	132	55	1.00 (Reference)		
Yes	81	50	2.258	(1.282-3.977)	0.005
Missing	2	0			
Jaundice					
No	197	95	1.00 (Reference)		
Yes	16	10	1.789	(0.626-5.114)	0.277
Missing	2	0			
Ascites					
No	202	99	1.00 (Reference)		
Yes	11	6	1.248	(0.369-4.220)	0.722
Missing	2	0			
Clinical parameters					
Albumin, g/L	122	53	0.891	(0.838-0.948)	<0.001
Missing	93	52			
Lymphocytes, mm^3					
< 1000	19	9	2.490	(0.923-6.719)	
≥ 1000	113	30	1.00 (Reference)		0.072
Missing	83	66			
Neutrophil-to-lymphocyte ratio					
< 5	92	21	1.00 (Reference)		
≥ 5	40	18	2.766	(1.255-6.099)	0.012
Missing	83	66			
CA19-9, UI/mL	189	82	1.000	(1.000-1.000)	0.155
Missing	26	23			
Previous treatment					

Primary tumor resection					
Yes	29	13	1.00 (Reference)		
No	186	92	1.205	(0.549-2.644)	0.643
Adjuvant chemotherapy					
Yes	24	12	1.00 (Reference)		
No	191	93	0.949	(0.406-2.218)	0.904

Logistic regression models used to estimate association of the parameters with FOLFOXIRI regimen. Values of $P<0.05$ were considered statistically significant and all tests were two-sided. OR: Odds ratio; CI: Confidence interval; WHO: World Health Organization; CA19-9: Carbohydrate antigen 19-9.

Supplementary Table 6 Unconditional multivariate logistic analysis of factors associated with FOLFOXIRI in first-line chemotherapy for the construction of the propensity score in patients with metastatic disease (*n* = 122).

Characteristics	Patients (*n*)	Patients treated with FOLFOXIRI (*n*)	OR (95%CI)	*P* value
Lymph node metastases				
No	94	49	1.00 (Reference)	
Yes	28	4	0.165 (0.049-0.562)	0.004
Peritoneal metastases				
No	96	38	1.00 (Reference)	
Yes	26	15	2.243 (0.793-6.344)	0.128
Pain†				
No	75	24	1.00 (Reference)	
Yes	47	29	3.124 (1.321-7.390)	0.010
Albumin, g/L	122	53	0.896 (0.839-0.956)	0.001

A propensity score was performed by an unconditional multivariable logistic regression model including lymph node and peritoneal metastases, pain and albumin level. Neutrophil-to-lymphocyte ratio was not selected in the propensity score process due to a high rate of missing data. Logistic regression models used to estimate association of the parameters with FOLFOXIRI regimen. Values of $P < 0.05$ were considered statistically significant and all tests were two-sided. OR: Odds ratio; CI: Confidence interval.

Supplementary Table 7 Patient characteristics of the propensity score - matched metastatic population according to first-line chemotherapy, *n* (%)

Characteristics	FOLFIRINOX (*n* = 32)	FOLFOXIRI (*n* = 32)	*P* value
Demographic parameters			
Age, median [IQR], years	59.8 [54.5-67.9]	60.4 [51.7-66.3]	0.669
Missing	0	0	
Gender			0.599
Male	20 (62.5)	22 (68.8)	
Female	12 (37.5)	10 (31.2)	
Familial history of cancer			1.000
No	9 (56.3)	18 (56.3)	
Yes	7 (43.7)	14 (43.7)	
Missing	16	0	
Personal history of cancer			1.000
No	27 (87.1)	27 (84.4)	
Yes	4 (12.9)	5 (15.6)	
Missing	1	0	
Pathologic parameters			
Stage at diagnosis			1.000
Localized	5 (15.6)	4 (12.5)	
Advanced	27 (84.4)	28 (87.5)	
Primary tumor site			0.701
Head	14 (45.2)	16 (50.0)	
Body and/or tail	17 (54.8)	16 (50.0)	
Histological grade			1.000
Well or Moderately differentiated	11 (68.8)	8 (66.7)	
Poorly differentiated or Undifferentiated	5 (31.2)	4 (33.3)	
Missing	16	20	
Tumor extension			
Number of metastatic sites			0.157
1	21 (65.6)	26 (81.3)	
≥ 2	11 (34.4)	6 (18.7)	
Lymph node metastases			1.000
No	28 (87.5)	28 (87.5)	

Yes	4 (12.5)	4 (12.5)	
Liver metastases			1.000
No	7 (21.9)	7 (21.9)	
Yes	25 (78.1)	25 (78.1)	
Peritoneal metastases			0.756
No	26 (81.3)	25 (78.1)	
Yes	6 (18.7)	7 (21.9)	
Lung metastases			0.740
No	26 (81.3)	27 (84.4)	
Yes	6 (18.7)	5 (15.6)	
Other metastases			0.238
No	29 (90.6)	32 (100.0)	
Yes	3 (9.4)	0 (0.0)	
Clinical parameters			
Performance status (WHO)			0.719
0	9 (29.0)	8 (25.0)	
≥ 1	22 (71.0)	24 (75.0)	
Missing	1	0	
Body mass index, kg/m^2	24.5 [21.3 -26.6]	23.9 [21.6-26.7]	0.537
Missing	3	0	
Pain			0.611
No	20 (62.5)	18 (56.3)	
Yes	12 (37.5)	14 (43.7)	
Jaundice			0.426
No	30 (93.8)	27 (84.4)	
Yes	2 (6.2)	5 (15.6)	
Missing	0	0	
Ascites			0.113
No	32 (100.0)	28 (87.5)	
Yes	0 (0.0)	4 (12.5)	
Biological parameters			
Albumin, median [IQR], g/L	38.1 [33.3-41.5]	38.0 [32.1-42.1]	0.899
Lymphocytes, median [IQR], mm^3			0.702
< 1000	5 (16.1)	4 (23.5)	
≥ 1000	26 (83.9)	13 (76.5)	
Missing	1	15	

Neutrophil-to-lymphocyte ratio, median [IQR]			0.393
< 5	22 (71.0)	10 (58.8)	
≥ 5	9 (29.0)	7 (41.2)	
Missing	1	15	
CA19-9, median [IQR], UI/mL	150.0 [32.1-8700.0]	1307.0 [108.0-8608.0]	0.439
Missing	0	3	
Previous treatment			
Primary tumor resection			1.000
Yes	3 (9.4)	4 (12.5)	
No	29 (90.6)	28 (87.5)	
Adjuvant chemotherapy			1.000
Yes	3 (9.4)	3 (9.4)	
No	29 (90.6)	29 (90.6)	

After propensity score matching, 32 patients each group (29.0% and 30.5% in the FOLFIRINOX and FOLFOXIRI groups, respectively) have been matched successfully. Baseline characteristics were no statistically different between the two matched groups. χ^2 tests or Fisher's exact tests used to compare proportions, and Wilcoxon tests used to compare continuous variables between FOLFIRINOX and FOLFOXIRI groups. All statistical tests were two-sided. CA19-9: Carbohydrate antigen 19-9; IQR: Interquartile range; WHO: World Health Organization.

Supplementary Table 8 Outcomes of the propensity score - matched metastatic population according to first-line chemotherapy, *n* (%)

Outcomes	FOLFIRINOX (*n* = 32)	FOLFOXIRI (*n* = 32)	*P* value
Number of cycles, median [IQR]	10.0 [4.0-12.0]	12.0 [4.0-17.0]	0.213
Missing	0	0	
RECIST best response			0.317
Complete or partial response	11 (40.8)	15 (60.0)	
Stability	10 (37.0)	5 (20.0)	
Progression	6 (22.2)	5 (20.0)	
Missing	5	7	
Toxicity of grade 3 or 4			0.362
No	22 (73.3)	20 (62.5)	
Yes	8 (26.7)	12 (37.5)	
Digestive	4 (1.3)	3 (0.9)	
Hematology	1 (0.3)	1 (0.3)	
Neurology	2 (0.6)	6 (1.8)	
Other	1 (0.3)	3 (0.3)	
Missing	2	0	
Reason for discontinuation			1.000
Progression	20 (62.5)	20 (62.5)	
Toxicity	4 (12.5)	5 (15.6)	
Other	8 (25.0)	7 (21.9)	
Maintenance			1.000
Yes	12 (37.5)	12 (37.5)	
No	20 (62.5)	20 (62.5)	
Second-line chemotherapy administration			1.000
Yes	22 (68.8)	22 (68.8)	
No	10 (31.2)	10 (31.2)	

χ^2 tests or Fisher's exact tests used to compare proportions, and Wilcoxon tests used to compare continuous variables between FOLFIRINOX and FOLFOXIRI groups. All statistical tests were two-sided. IQR: Interquartile range.



Supplementary Figure 1 Unconditional multivariable logistic regression ROC Curve analysis.



Supplementary Figure 2 Distribution of the probability estimated of the propensity score by the logistic multivariable model in FOLFIRINOX and FOLFOXIRI groups.



Supplementary Figure 3 Kaplan-Meier curves of (A) overall survival and (B) progression free survival for the FOLFIRINOX and FOLFOXIRI groups in the entire metastatic population. Values of the log-rank test P < 0.05 were considered statistically significant, and all tests were two-sided. CI: confidence interval; HR: hazard ratio.



Supplementary Figure 4 Unconditional multivariable logistic regression receiver operating characteristic curve analysis in patients with metastatic disease.



Supplementary Figure 5 Distribution of the probability estimated of the propensity score by the logistic multivariable model in FOLFIRINOX and FOLFOXIRI groups in patients with metastatic disease. After a propensity score value calculated for each patient, patients treated with FOLFOXIRI regimen were matched, with a caliper of 0.10 and ratio of 1:1, with patients in the FOLFIRINOX group.


A
FOLFOXIRI: median time = 9.6 months, 95%CI 5.7 to 17.9
FOLFIRINOX: median time = 11.6 months, 95%CI 7.1 to 14.1
HR = 0.94, 95%CI 0.54 to 1.61
Logrank p=0.8102
Overall Survival probability
Time since chemotherapy initiation (Months)
FOLFOXIRI 32 26 22 18 13 12 10 9 8 7 6 4 4
FOLFIRINOX 32 26 22 16 12 8 6 5 3 3 3 2 1


B
FOLFOXIRI: median time = 6.5 months, 95%CI 2.5 to 9.4
FOLFIRINOX: median time = 6.5 months, 95%CI 3.0 to 8.8
HR = 0.94, 95%CI 0.55 to 1.61
Logrank p=0.8268
Progression Free Survival probability
Time since chemotherapy initiation (Months)
FOLFOXIRI 32 21 18 11 6 3 3 1 1 1 1 1 1
FOLFIRINOX 32 22 17 8 4 2 1 1 1 1 1 1 1

Supplementary Figure 6 Kaplan-Meier curves of (A) overall survival and (B) progression free survival for the FOLFIRINOX and FOLFOXIRI groups in the propensity score-matched metastatic population. Values of the log-rank test $P < 0.05$ were considered statistically significant, and all tests were two-sided. CI: confidence interval; HR: hazard ratio.